Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIPAC-003: Eftilagimod Alpha + Paclitaxel in Metastatic Breast Cancer
NCT05747794Phase 3Terminated
- Sponsor
- Immutep Limited
- Start
- May 2023
- Primary completion
- Apr 2026
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Fc-Fusion Proteins
- Countries
- 5
01
Overview
A Phase 3 trial of eftilagimod alpha in breast cancer, sponsored by Immutep Limited. Started May 2023; status: terminated.
02
Drugs
eftilagimod alpha
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05747794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05747794.